Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Buhrlage SJ"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lantermans HC; Department of Pathology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Cancer Biology and Immunology - Target & Therapy Discovery, Amsterdam, The Netherlands., Ma F; Department of Pathology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Cancer Biology and Immunology - Target & Therapy Discovery, Amsterdam, The Netherlands., Kuil A; Department of Pathology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Cancer Biology and Immunology - Target & Therapy Discovery, Amsterdam, The Netherlands., van Kesteren S; Department of Pathology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Cancer Biology and Immunology - Target & Therapy Discovery, Amsterdam, The Netherlands., Yasinoglu S; Department of Pathology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Cancer Biology and Immunology - Target & Therapy Discovery, Amsterdam, The Netherlands., Yang G; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Blueprint Medicines, Cambridge, MA, USA., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Wang J; Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gray NS; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA., Kersten MJ; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands., Treon SP; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Pals ST; Department of Pathology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Cancer Biology and Immunology - Target & Therapy Discovery, Amsterdam, The Netherlands., Spaargaren M; Department of Pathology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. marcel.spaargaren@amsterdamumc.nl.; Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands. marcel.spaargaren@amsterdamumc.nl.; Cancer Center Amsterdam (CCA), Cancer Biology and Immunology - Target & Therapy Discovery, Amsterdam, The Netherlands. marcel.spaargaren@amsterdamumc.nl.
Publikováno v:
Leukemia [Leukemia] 2024 Jul; Vol. 38 (7), pp. 1570-1580. Date of Electronic Publication: 2024 Mar 07.
Autor:
Chowdhury B; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Garg S; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Ni W; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Sanchez D; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Akatsu T; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Forrester W; Novartis Pharma AG, 4056 Basel, Switzerland., Harrington E; Novartis Pharma AG, 4056 Basel, Switzerland., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Publikováno v:
Cancers [Cancers (Basel)] 2024 Mar 28; Vol. 16 (7). Date of Electronic Publication: 2024 Mar 28.
Autor:
Sahu I; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Zhu H; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA; Center for Emergent Drug Targets, USA. Electronic address: saraj_buhrlage@dfci.harvard.edu., Marto JA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Emergent Drug Targets, USA. Electronic address: jarrod_marto@dfci.harvard.edu.
Publikováno v:
Biochimica et biophysica acta. Gene regulatory mechanisms [Biochim Biophys Acta Gene Regul Mech] 2023 Jun; Vol. 1866 (2), pp. 194940. Date of Electronic Publication: 2023 Apr 29.
Autor:
Chappell DL; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Sandhu PK; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Wong JP; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Bhatt AP; Department of Medicine, Division of Gastroenterology and Hepatology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Temple BRS; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; R. L. Juliano Structural Bioinformatics Core Facility, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Center for Structural Biology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Major MB; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Cell and Developmental Biology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Damania B; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Publikováno v:
Journal of virology [J Virol] 2023 Mar 30; Vol. 97 (3), pp. e0176322. Date of Electronic Publication: 2023 Mar 06.
Autor:
Chan WC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Magin RS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Girardi NM; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA., Hu W; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Tarazona Guzman MI; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Starnbach CA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Felix A; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Adelmant G; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Varca AC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Hu B; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Bratt AS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., DaSilva E; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Schauer NJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jaen Maisonet I; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Dolen EK; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ayala AX; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Marto JA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. jarrod_marto@dfci.harvard.edu., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2023 Feb 08; Vol. 14 (1), pp. 686. Date of Electronic Publication: 2023 Feb 08.
Autor:
Bae M; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Blavatnik Institute, Boston, MA, USA.; College of Pharmacy, Gachon University, Incheon, South Korea., Cassilly CD; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Blavatnik Institute, Boston, MA, USA., Liu X; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Blavatnik Institute, Boston, MA, USA.; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Park SM; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Tusi BK; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chen X; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Kwon J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Blavatnik Institute, Boston, MA, USA.; Natural Product Informatics Research Center, Korea Institute of Science and Technology (KIST), Ganeung, South Korea., Filipčík P; Biochemistry Department, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.; SBGrid Consortium, Harvard Medical School, Blavatnik Institute, Boston, MA, USA., Bolze AS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Liu Z; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Vlamakis H; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Graham DB; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Buhrlage SJ; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Blavatnik Institute, Boston, MA, USA.; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Xavier RJ; Broad Institute of MIT and Harvard, Cambridge, MA, USA. xavier@molbio.mgh.harvard.edu.; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. xavier@molbio.mgh.harvard.edu.; Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. xavier@molbio.mgh.harvard.edu., Clardy J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Blavatnik Institute, Boston, MA, USA. jon_clardy@hms.harvard.edu.
Publikováno v:
Nature [Nature] 2022 Aug; Vol. 608 (7921), pp. 168-173. Date of Electronic Publication: 2022 Jul 27.
Autor:
Zhu H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States., Mellors JS; 908 Devices Inc., Boston, Massachusetts 02210, United States., Chan WC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States., Thompson JW; 908 Devices Inc., Boston, Massachusetts 02210, United States., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States., Tavares I; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States., Bratt AS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States., Decker J; Bruker Daltonics GmbH & Co. KG, Bremen 28359, Germany., Krause M; Bruker Daltonics GmbH & Co. KG, Bremen 28359, Germany., Kruppa G; Bruker S.R.O., District Brno-City 61900 Czech Republic., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Publikováno v:
Analytical chemistry [Anal Chem] 2022 Jul 12; Vol. 94 (27), pp. 9508-9513. Date of Electronic Publication: 2022 Jun 21.
Autor:
Lee PC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Klaeger S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Le PM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Korthauer K; Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada., Cheng J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, New Hampshire, USA., Ananthapadmanabhan V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Frost TC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA., Stevens JD; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Wong AY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Tarren AY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Chea VA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Carulli IP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lemvigh CK; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark., Pedersen CB; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.; Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Gartin AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA., Sarkizova S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA., Wright KT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Li LW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Nomburg J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA., Li S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Huang T; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology., Pomerance L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Immunology, and., Doherty LM; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology.; Department of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Apffel AM; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Wallace LJ; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Rachimi S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Felt KD; Center for Immuno-Oncology and., Wolff JO; Center for Immuno-Oncology and., Witten E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Zhang W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lane WJ; Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Zhang G; Department of Computer Science, Metropolitan College, Boston University, Boston, Massachusetts, USA., Olsen LR; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.; Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Thakuria M; Harvard Medical School, Boston, Massachusetts, USA.; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Merkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts, USA., Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Center for Immuno-Oncology and., Clauser KR; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Starrett GJ; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA., Doench JG; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology., Carr SA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA.; Merkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.; Department of Computer Science, Metropolitan College, Boston University, Boston, Massachusetts, USA.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2022 Jul 01; Vol. 132 (13).
Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes.
Autor:
Doherty LM; Harvard Medical School (HMS) Library of Integrated Network-based Cellular Signatures (LINCS) Center, Cambridge, United States.; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, United States., Mills CE; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, United States., Boswell SA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, United States., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Hoyt CT; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, United States., Gyori B; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, United States., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Sorger PK; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, United States.
Publikováno v:
ELife [Elife] 2022 Jun 23; Vol. 11. Date of Electronic Publication: 2022 Jun 23.